Cargando…

CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Platinum-based chemotherapy is the first-line treatment for small cell lung cancer (SCLC). However, due to patients developing a resistance to the drug, most experience relapse and their cancer can become untreatable. A large number of recent studies have found that platinum drug sensitivity of vari...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Yonglin, Qiu, Zhengang, Yao, Zifu, Lin, Anqi, Qin, Yimin, Sha, Ruizhan, Wei, Ting, Wang, Yanru, Cheng, Quan, Zhang, Jian, Luo, Peng, Shen, Weitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787262/
https://www.ncbi.nlm.nih.gov/pubmed/35087829
http://dx.doi.org/10.3389/fcell.2021.770811
_version_ 1784639322689896448
author Yi, Yonglin
Qiu, Zhengang
Yao, Zifu
Lin, Anqi
Qin, Yimin
Sha, Ruizhan
Wei, Ting
Wang, Yanru
Cheng, Quan
Zhang, Jian
Luo, Peng
Shen, Weitao
author_facet Yi, Yonglin
Qiu, Zhengang
Yao, Zifu
Lin, Anqi
Qin, Yimin
Sha, Ruizhan
Wei, Ting
Wang, Yanru
Cheng, Quan
Zhang, Jian
Luo, Peng
Shen, Weitao
author_sort Yi, Yonglin
collection PubMed
description Platinum-based chemotherapy is the first-line treatment for small cell lung cancer (SCLC). However, due to patients developing a resistance to the drug, most experience relapse and their cancer can become untreatable. A large number of recent studies have found that platinum drug sensitivity of various cancers is affected by specific gene mutations, and so with this study, we attempted to find an effective genetic biomarker in SCLC patients that indicates their sensitivity to platinum-based drugs. To do this, we first analyzed whole exome sequencing (WES) and clinical data from two cohorts to find gene mutations related to the prognosis and to the platinum drug sensitivity of SCLC patients. The cohorts used were the Zhujiang cohort (N = 138) and the cohort reported by George et al. (N = 101). We then carried out gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) to investigate possible molecular mechanisms through which these gene mutations affect patient prognosis and platinum drug sensitivity. We found that for SCLC patients, CAMSAP1 mutation can activate anti-tumor immunity, mediate tumor cell apoptosis, inhibit epithelial-mesenchymal transition (EMT), improve prognosis, and improve platinum drug sensitivity, suggesting that CAMSAP1 mutation may be a potential biomarker indicating platinum drug sensitivity and patient prognosis in SCLC.
format Online
Article
Text
id pubmed-8787262
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87872622022-01-26 CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy Yi, Yonglin Qiu, Zhengang Yao, Zifu Lin, Anqi Qin, Yimin Sha, Ruizhan Wei, Ting Wang, Yanru Cheng, Quan Zhang, Jian Luo, Peng Shen, Weitao Front Cell Dev Biol Cell and Developmental Biology Platinum-based chemotherapy is the first-line treatment for small cell lung cancer (SCLC). However, due to patients developing a resistance to the drug, most experience relapse and their cancer can become untreatable. A large number of recent studies have found that platinum drug sensitivity of various cancers is affected by specific gene mutations, and so with this study, we attempted to find an effective genetic biomarker in SCLC patients that indicates their sensitivity to platinum-based drugs. To do this, we first analyzed whole exome sequencing (WES) and clinical data from two cohorts to find gene mutations related to the prognosis and to the platinum drug sensitivity of SCLC patients. The cohorts used were the Zhujiang cohort (N = 138) and the cohort reported by George et al. (N = 101). We then carried out gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) to investigate possible molecular mechanisms through which these gene mutations affect patient prognosis and platinum drug sensitivity. We found that for SCLC patients, CAMSAP1 mutation can activate anti-tumor immunity, mediate tumor cell apoptosis, inhibit epithelial-mesenchymal transition (EMT), improve prognosis, and improve platinum drug sensitivity, suggesting that CAMSAP1 mutation may be a potential biomarker indicating platinum drug sensitivity and patient prognosis in SCLC. Frontiers Media S.A. 2022-01-11 /pmc/articles/PMC8787262/ /pubmed/35087829 http://dx.doi.org/10.3389/fcell.2021.770811 Text en Copyright © 2022 Yi, Qiu, Yao, Lin, Qin, Sha, Wei, Wang, Cheng, Zhang, Luo and Shen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Yi, Yonglin
Qiu, Zhengang
Yao, Zifu
Lin, Anqi
Qin, Yimin
Sha, Ruizhan
Wei, Ting
Wang, Yanru
Cheng, Quan
Zhang, Jian
Luo, Peng
Shen, Weitao
CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
title CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
title_full CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
title_fullStr CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
title_full_unstemmed CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
title_short CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
title_sort camsap1 mutation correlates with improved prognosis in small cell lung cancer patients treated with platinum-based chemotherapy
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787262/
https://www.ncbi.nlm.nih.gov/pubmed/35087829
http://dx.doi.org/10.3389/fcell.2021.770811
work_keys_str_mv AT yiyonglin camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT qiuzhengang camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT yaozifu camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT linanqi camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT qinyimin camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT sharuizhan camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT weiting camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT wangyanru camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT chengquan camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT zhangjian camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT luopeng camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT shenweitao camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy